Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Fibrocell Science Inc

+ Add to Watchlist


3.9900 USD 0.0700 1.79%

As of 20:10:00 ET on 05/27/2015.

Snapshot for Fibrocell Science Inc (FCSC)

Open: 4.0100 Day's Range: 3.9100 - 4.0500 Volume: 84,503
Previous Close: 3.9200 52wk Range: 2.2801 - 5.9900 1-Yr Rtn: +34.34%

Stock Chart for FCSC

No chart data available.
  • FCSC:US 3.9900
  • 1D
  • 1M
  • 1Y
Interactive FCSC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for FCSC

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.5325
Est. EPS (USD) (12/2015) -0.6550
Est. PEG Ratio -
Market Cap (M USD) 163.14
Shares Outstanding (M) 40.89
30 Day Average Volume 199,340
Price/Book (mrq) 7.3237
Price/Sale (ttm) 497.0407
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for FCSC

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for FCSC

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on treatments for skin and connective tissue diseases. The Company is developing an autologous fibroblast therapy for chronic dysphonia. Fibrocell's gene-therapy program uses gene-modified autologous fibroblasts to treat RDEB. The Company also has a gene-therapy program for linear scleroderma.

David M PernockChairman/CEOKeith Alan GoldanSenior VP/CFO/Treasurer/Secy
Robert SheroffVP:Technical OperationsKimberly M SmithController
More Company Profile & Key Executives for FCSC

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil